Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD)Stefano Cascinu, Rodolfo Passalacqua, Davide Pastorelli et al.|Annals of Oncology|2015Cited by 0